The Current Status and Trend of Clinical Pharmacology and Clinical Care

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue of the journal Vaccines entitled “The Current Status and Trend of Clinical Pharmacology and Clinical Care”. Clinical pharmacology encompasses human investigations through randomised controlled trials (RCTs) and evaluating benefit–risk ratios in large populations. Although other designs (pragmatic trials, platform trials, and so on) are beginning to emerge, randomised controlled trials (RCTs) are still the gold standard for determining the efficacy of human medications. Improvements in drug development may be possible thanks to recent developments in research using healthy volunteers and contributions made by new technologies such as artificial intelligence, machine learning, and trials conducted over the internet. In the realm of precision medicine, identifying novel disease phenotypes and endotypes will presumably be helpful in locating new pharmacological targets, patients who respond well to treatments, and patients at risk for adverse drug reactions. The growth of translational research through academic and private cooperation, the open and honest exchange of clinical trial data, and the enhancement of communication between pharmacologists, patients, and the general public are critical areas for action. On the other hand, developing nucleic acids and phytomolecule-based vaccines and modulating various players of the immune system to address multiple diseases is still a grey area.

This Special Issue aims to achieve a more extensive understanding of current scientific knowledge and trends in clinical pharmacology and care. This Special Issue focuses on the recent scientific and technical progress made in this field. Based on your extensive knowledge and experience, we invite you to contribute with an original review or research paper, to highlight any of the following: (i) clinical immunology; (ii) research based on traditional formulations already in clinical use for modifying the immune system to address diseases such as allergy, cardiovascular diseases, or cancer; (ii) vaccine development and clinical trials in a wide variety of diseases in humans; (iii) phytomolecule- and nucleic acid-based vaccine drug delivery, development and challenges; or (iv) recent advances in novel prophylactic and therapeutic vaccines in clinical trials.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

1. Translational, predictive, and personalised medicine new therapeutic modalities such as gene and cell therapies
2. Pharmacogenomics
3. Proteomics and metabolomics
4. Bioinformation and applied system biology
5. Areas that complement the study of pharmacokinetics and pharmacodynamics
6. Human investigations and clinical trials
7. Pharmacovigilance
8. Pharmacoepidemiology
9. Pharmacometrics
10. Population pharmacology
11. Clinical immunology
12. Immunopathogenesis in the vaccine domain or otherwise
13. Traditionally used formulations in AYUSH hospitals, reverse pharmacology affecting the immune system in allergy, cancer and other diseases
14. Challenges associated with vaccine development of RNA therapies and phytomolecules in humans.

We look forward to receiving your contributions.

Dr. Imran Kazmi
Prof. Dr. Sanmoy Karmakar
Guest Editors
Md. Adil Shaharyar
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• clinical
• immunology
• vaccines
• phytomolecules
• biomarkers
• RNA theraphy
• epigenetic modulators